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TEXT: 
A 64-year old woman was addressed to the endocrinology clinics, following the observation of  
subclinical hypothyroidism and positive anti-TPO auto-antibodies, (TSH levels 6.28 uUI/ml). 
Ultrasound examination showed a diffusely enlarged heterogeneous hypoechoic right lobe, with two 
micronodules (3 and 7 mm) and the absence of the left thyroid lobe... The patient started 
levothyroxine (L-T4) replacement therapy (50 µg/day), remaining euthyroid for almost four years. 
In August 2014, she presented tiredness, tremors and palpitations  with markedly increased free 
thyroid hormone and suppressed TSH levels. L-T4 therapy was discontinued, with no clinical 
improvement. On September 2014, the laboratory findings confirmed the persistence of 
thyrotoxicosis. The 99Tc scintiscan showed increased uptake in the right thyroid lobe, suggesting the 
diagnosis of Graves’ disease which was corroborated by the demonstration of highly positive 
(46.2UI/L) TSH receptor antibodies (TRAb), measured using a 2nd generation TRAK human 
lumitest (Thermofisher, AG, Henningsdorf/ Berlin, Germany; normal value<1.8 U/L). 
Consequently, the patient started methymazole (MMI) treatment (30 mg/day). On November 2014, 
Graves’ Orbitopathy (GO) with symptomatic vertical diplopia appeared, requiring 8^ prisms for 
correction of constant diplopia. The Nuclear Magnetic Imaging of the orbits showed thickening of 
extra-ocular muscles (medial and inferior right rectus and bilaterally superior recti). Further follow-
up showed rapid progression of the GO, with deterioration of vertical diplopia. The 
ophthalmological assessment, according to the EUGOGO guidelines (1) demonstrated bilateral 
active GO with spontaneous orbital pain, chemosis, lid edema and hyperemia resulting in a clinical 
activity score (CAS) of 5/10. The patient presented also constant diplopia, a proptosis of 23.5/22 
mm and significant worsening of eye motility. The severity NOSPECS score was 2B3A4B5060. 
The persistence of hyperthyroidism (TSH 0.01 mU/L, FT4 22.3 pmol/l and FT3 10.1 pmol/l) and 
elevated TRAb levels (41.4 U/L) required an increase of MMI to 40 mg/day. High doses of 
intravenous methylprednisolone (IVMP) were also administered once a week for 12 weeks (six 
pulses of 830 mg followed by six more pulses of 415 mg with a cumulative dose 7.5 g) from 
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January to March 2015. Six weeks after completing corticosteroid treatment, the patient was re-
examined, GO resulted inactive (CAS 2/10). Monthly follow up showed progressive improvement 
of both inflammatory manifestations and eye motility. Euthyroidism was maintained, under 
escalating MMI dose which was discontinued  on September 2015.GO persisted inactive, with only 
inconstant diplopia, a CAS of 1/10 and a severity NOSPECS score 2A3A405060GO. The patient 
could eventually resume her daily activities, including bicycle riding (February 2016). The patient 
remained euthyroid  during the remaining follow-up (TSH 2.86 uUI/ml and undetectable TRAb on 
January 2018). 
Thyroid hemiagenesis is rare, with a prevalence estimated to 0.2% at systematic ultrasound 
screening (2). Its association with Graves’ disease is exceptional and only 21 patients have been 
previously reported in the literature (3). Interestingly, spontaneous conversion from 
hyperthyroidism to hypothyroidism or long-term remission has been previously reported in two 
cases.  A third case, unresponsive to oral steroids underwent orbital decompression. Notably, the 
present report illustrates the second documented case of GO successfully treated with IVMP 
administration in thyroid hemiagenesis.  
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Legend to the Figure 
Figure 1 clinical assessment of the patient 
Panel A: Ultrasound examination demostrating the absence of the left thyroid lobe and the presence 
of a diffusely enlarged heterogeneous hypoechoic right lobe.  
 Panel B: 99m Tc Thyroid scan confirming an increased uptake of the right thyroid lobe.  
Panel C: MRI imaging of the orbit, showing thickening of extra-ocular muscles (medial and inferior 
right rectus and bilaterally superior recti) 
Panel D: Orthoptic evaluation. Eye motility was calculated as the sum of ductions in each eye and 
the asymmetry as the difference of the ductions between the two eyes, measured in degrees.  The 
dashed line represents the mean results of normal controls, the gray area the ductions measured in 
the patient. Total Motility Score (TMS) was calculated as the sum of ductions in each eye and a bi-
ocular TMS  (in gray) as the sum of both eyes TMS. The Asymmetry Ratio (in black), was 
calculated as the differences of the ductions between the two eyes divided by the mean Asymmetry 
Ratio measured in normal controls. IVMP treatment was able to improve right eye motility leading 
to a reduction of diplopia.  
